EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Enhancing Prenatal Genetic Evaluation Through the Combination of Single‐Gene Non‐Invasive Prenatal Screening and Prenatal Imaging

Sarah Araji, Jennifer L Cohen iD

Prenatal Diagnosis · 2026

DOI: 10.1002/pd.70204 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Prenatal Diagnosis, 2026. Verfasst von Sarah Araji und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, …. Hauptthemen laut MEDLINE: Noninvasive Prenatal Testing, Prenatal Diagnosis, Genetic Testing. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cell free DNA (cfDNA) screening for common aneuploidies is now widely integrated into prenatal care, and recent advances in next‐generation sequencing, enhanced by unique molecular indexing methodology, have enabled cfDNA for selected single‐gene disorders (cfDNA‐SGD). Commercially available cfDNA‐SGD panels target predominantly either de novo autosomal dominant or X‐linked conditions that have recognizable prenatal or neonatal phenotypes. However, it remains a screening modality that relies on placental cell‐free DNA, and encounters limitations. In this review, we summarize a currently available cfDNA‐SGD panel that screens for 25 autosomal or X‐linked dominant conditions corresponding to 30 unique genes, with several genes contributing to multiple conditions on the panel. We highlight the potentially associated prenatal and postnatal phenotypes and the imaging modalities that may help refine a prenatal genetic evaluation. We also discuss how ultrasound, fetal echocardiography, and fetal MRI across all trimesters can refine the prenatal differential diagnosis and help contextualize cfDNA‐SGD results, while emphasizing that imaging findings remain the primary guide for management and that confirmatory diagnostic testing is required before clinical decisions and action.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Noninvasive Prenatal TestingPrenatal DiagnosisGenetic TestingHumansPregnancyFemaleUltrasonography, PrenatalCell-Free Nucleic AcidsMagnetic Resonance Imaging

Substanzen

Cell-Free Nucleic Acids

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.
  • Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
  • Department of Pediatrics, Division of Medical Genetics, Duke University, Durham, North Carolina, USA.
  • Department of Obstetrics and Gynecology, Duke University, Durham, North Carolina, USA.
  • Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA.

ORCID-Profile: Jennifer L Cohen

Förderung

  • NICHD NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Araji, S., & Cohen, J. L. (2026). Enhancing Prenatal Genetic Evaluation Through the Combination of Single‐Gene Non‐Invasive Prenatal Screening and Prenatal Imaging. Prenatal Diagnosis. https://doi.org/10.1002/pd.70204

Vancouver

Araji S, Cohen JL. Enhancing Prenatal Genetic Evaluation Through the Combination of Single‐Gene Non‐Invasive Prenatal Screening and Prenatal Imaging. Prenatal Diagnosis. 2026. doi:10.1002/pd.70204

BibTeX
@article{Araji2026,
  author = {Araji, Sarah and Cohen, Jennifer L},
  title = {Enhancing Prenatal Genetic Evaluation Through the Combination of Single‐Gene Non‐Invasive Prenatal Screening and Prenatal Imaging},
  journal = {Prenatal Diagnosis},
  year = {2026},
  doi = {10.1002/pd.70204}
}
Kostenlos starten →